ACLARIS THERAPEUTICS INC. - COMMON STOCK

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

29 4 2025 06:00:32 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

22 4 2025 05:59:08 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

04 3 2025 06:00:05 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

27 2 2025 05:59:55 提供 Nasdaq GlobeNewswire

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

12 2 2025 05:50:01 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

30 1 2025 15:01:21 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

06 1 2025 15:30:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

03 12 2024 15:30:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

26 11 2024 15:30:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

19 11 2024 08:45:01 提供 NetDania Notify

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

18 11 2024 08:52:02 提供 NetDania Notify

Aclaris Therapeutics Announces $80 Million Private Placement

18 11 2024 07:10:41 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

18 11 2024 07:10:04 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

13 11 2024 08:53:10 提供 NetDania Notify

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

11 11 2024 08:48:00 提供 NetDania Notify

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

06 11 2024 06:00:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

17 9 2024 06:00:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

10 9 2024 06:00:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

07 8 2024 06:00:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

16 7 2024 15:01:43 提供 Nasdaq GlobeNewswire